Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First thalidomide clinical trial in multiple myeloma: a decade.
van Rhee F, Dhodapkar M, Shaughnessy JD Jr, Anaissie E, Siegel D, Hoering A, Zeldis J, Jenkins B, Singhal S, Mehta J, Crowley J, Jagannath S, Barlogie B. van Rhee F, et al. Among authors: hoering a. Blood. 2008 Aug 15;112(4):1035-8. doi: 10.1182/blood-2008-02-140954. Epub 2008 May 23. Blood. 2008. PMID: 18502827 Free PMC article. Clinical Trial.
Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease.
Barlogie B, van Rhee F, Shaughnessy JD Jr, Epstein J, Yaccoby S, Pineda-Roman M, Hollmig K, Alsayed Y, Hoering A, Szymonifka J, Anaissie E, Petty N, Kumar NS, Srivastava G, Jenkins B, Crowley J, Zeldis JB. Barlogie B, et al. Among authors: hoering a. Blood. 2008 Oct 15;112(8):3122-5. doi: 10.1182/blood-2008-06-164228. Epub 2008 Jul 31. Blood. 2008. PMID: 18669874 Free PMC article. Clinical Trial.
Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival.
Nair B, Shaughnessy JD Jr, Zhou Y, Astrid-Cartron M, Qu P, van Rhee F, Anaissie E, Alsayed Y, Waheed S, Hollmig K, Szymonifka J, Petty N, Hoering A, Barlogie B. Nair B, et al. Among authors: hoering a. Blood. 2009 Jun 25;113(26):6572-5. doi: 10.1182/blood-2009-02-207803. Epub 2009 Apr 23. Blood. 2009. PMID: 19389881 Free PMC article.
Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.
Nair B, van Rhee F, Shaughnessy JD Jr, Anaissie E, Szymonifka J, Hoering A, Alsayed Y, Waheed S, Crowley J, Barlogie B. Nair B, et al. Among authors: hoering a. Blood. 2010 May 27;115(21):4168-73. doi: 10.1182/blood-2009-11-255620. Epub 2010 Feb 2. Blood. 2010. PMID: 20124509 Free PMC article. Clinical Trial.
Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy.
van Rhee F, Szymonifka J, Anaissie E, Nair B, Waheed S, Alsayed Y, Petty N, Shaughnessy JD Jr, Hoering A, Crowley J, Barlogie B. van Rhee F, et al. Among authors: hoering a. Blood. 2010 Aug 26;116(8):1220-7. doi: 10.1182/blood-2010-01-264333. Epub 2010 May 25. Blood. 2010. PMID: 20501894 Free PMC article.
Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of SWOG S0120).
Papanikolaou X, Rosenthal A, Dhodapkar M, Epstein J, Khan R, van Rhee F, Jethava Y, Waheed S, Zangari M, Hoering A, Crowley J, Alapat D, Davies F, Morgan G, Barlogie B. Papanikolaou X, et al. Among authors: hoering a. Blood Cancer J. 2016 Mar 25;6(3):e410. doi: 10.1038/bcj.2016.19. Blood Cancer J. 2016. PMID: 27015287 Free PMC article. No abstract available.
94 results